
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6274774/publications.pdf Version: 2024-02-01



INÃAS RALDEIDAS

#	Article	IF	CITATIONS
1	Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. Brain, 2022, 145, 700-712.	3.7	16
2	Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia. European Journal of Neurology, 2022, 29, 36-46.	1.7	14
3	Mitochondriotropic antioxidant based on caffeic acid AntiOxCIN4 activates Nrf2-dependent antioxidant defenses and quality control mechanisms to antagonize oxidative stress-induced cell damage. Free Radical Biology and Medicine, 2022, 179, 119-132.	1.3	14
4	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
5	The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence. Biomedicines, 2022, 10, 315.	1.4	15
6	Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers. Alzheimer's Research and Therapy, 2022, 14, 9.	3.0	2
7	Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis. Journal of Neuroinflammation, 2022, 19, 44.	3.1	4
8	Lewy body dementia is associated with an increased risk of atrial fibrillation: A case-control study. Journal of Clinical Neuroscience, 2022, 99, 62-65.	0.8	2
9	Redox profiles of amyotrophic lateral sclerosis lymphoblasts with or without known SOD1 mutations. European Journal of Clinical Investigation, 2022, 52, e13798.	1.7	3
10	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 659-667.	0.9	21
11	Neuropsychological profile of amyloidâ€positive versus amyloidâ€negative amnestic Mild Cognitive Impairment. Journal of Neuropsychology, 2021, 15, 41-52.	0.6	11
12	Estimates of Geriatric Delirium Frequency in Noncardiac Surgeries and Its Evaluation Across the Years: A Systematic Review and Meta-Analysis. Journal of the American Medical Directors Association, 2021, 22, 613-620.e9.	1.2	20
13	Neuropsychological features of progranulin-associated frontotemporal dementia: a nested case-control study. Neural Regeneration Research, 2021, 16, 910.	1.6	3
14	Sex-dependent vulnerability of fetal nonhuman primate cardiac mitochondria to moderate maternal nutrient reduction. Clinical Science, 2021, 135, 1103-1126.	1.8	15
15	DNA Methylation Is Correlated with Oxidative Stress in Myelodysplastic Syndrome—Relevance as Complementary Prognostic Biomarkers. Cancers, 2021, 13, 3138.	1.7	6
16	Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients. Frontiers in Cell and Developmental Biology, 2021, 9, 701328.	1.8	3
17	Cognitive Trajectories Following Acute Infection in Older Patients With and Without Cognitive Impairment: An 1-Year Follow-Up Study. Frontiers in Psychiatry, 2021, 12, 754489.	1.3	1
18	Cell quality control mechanisms maintain stemness and differentiation potential of P19 embryonic carcinoma cells. Autophagy, 2020, 16, 313-333.	4.3	18

#	Article	IF	CITATIONS
19	APOE ɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 587-601.	1.2	0
20	Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2020, 21, 8680.	1.8	13
21	Patients with progranulin mutations overlap with the progressive dysexecutive syndrome: towards the definition of a frontoparietal dementia phenotype. Brain Communications, 2020, 2, fcaa126.	1.5	3
22	A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia. Journal of Neurology, 2020, 267, 2567-2581.	1.8	6
23	C-reactive protein as a predictor of mild cognitive impairment conversion into Alzheimer's disease dementia. Experimental Gerontology, 2020, 138, 111004.	1.2	18
24	Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 785-796.	1.2	6
25	A different vision of translational research in biomarker discovery: a pilot study on circulatory mitochondrial proteins as Parkinson's disease potential biomarkers. Translational Neurodegeneration, 2020, 9, 11.	3.6	4
26	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nature Communications, 2020, 11, 619.	5.8	67
27	Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. Molecular Neurobiology, 2019, 56, 2811-2821.	1.9	20
28	Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer's disease. Epilepsy and Behavior, 2019, 98, 207-209.	0.9	22
29	Lower CSF Amyloid-Beta1–42 Predicts a Higher Mortality Rate in Frontotemporal Dementia. Diagnostics, 2019, 9, 162.	1.3	3
30	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
31	Association between Adipokines and Biomarkers of Alzheimer's Disease: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2019, 67, 725-735.	1.2	18
32	Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 91.	3.0	78
33	Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients. Biomolecules, 2019, 9, 800.	1.8	8
34	Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 2.	3.0	19
35	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer's and Dementia, 2018, 14, 751-763.	0.4	61
36	Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 61, 1097-1105.	1.2	7

#	Article	IF	CITATIONS
37	Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration. Journal of Alzheimer's Disease, 2018, 64, S647-S657.	1.2	10
38	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
39	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
40	P1â€280: CEREBROSPINAL FLUID Aβ42 AND TAU MEASUREMENT ON LUMIPULSE® G: ANALYTICAL VERIFICATIO AND METHOD COMPARISON. Alzheimer's and Dementia, 2018, 14, P390.	N 0.4	0
41	Adenosine Deaminase Two and Immunoglobulin M Accurately Differentiate Adult Sneddon's Syndrome of Unknown Cause. Cerebrovascular Diseases, 2018, 46, 257-264.	0.8	15
42	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
43	Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2018, 10, 33.	3.0	63
44	The Head Turning Sign in Dementia and Mild Cognitive Impairment: Its Relationship to Cognition, Behavior, and Cerebrospinal Fluid Biomarkers. Dementia and Geriatric Cognitive Disorders, 2018, 46, 42-49.	0.7	6
45	Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis. Molecular Carcinogenesis, 2017, 56, 130-148.	1.3	15
46	Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients. Neuroscience Letters, 2017, 641, 101-106.	1.0	14
47	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
48	Phytoestrogen coumestrol improves mitochondrial activity and decreases oxidative stress in the brain of ovariectomized Wistar-Han rats. Journal of Functional Foods, 2017, 34, 329-339.	1.6	7
49	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
50	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113
51	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
52	Multiple sclerosis: Association of gelatinase B/matrix metalloproteinase-9 with risk and clinical course the disease. Multiple Sclerosis and Related Disorders, 2017, 11, 71-76.	0.9	15
53	Development of a Mitochondriotropic Antioxidant Based on Caffeic Acid: Proof of Concept on Cellular and Mitochondrial Oxidative Stress Models. Journal of Medicinal Chemistry, 2017, 60, 7084-7098.	2.9	47
54	Prognosis of Early-Onset vs. Late-Onset Mild Cognitive Impairment: Comparison of Conversion Rates and Its Predictors. Geriatrics (Switzerland), 2016, 1, 11.	0.6	38

#	Article	IF	CITATIONS
55	Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiology of Aging, 2016, 41, 200.e1-200.e5.	1.5	96
56	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
57	CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt–Jakob disease suspected cases with inconclusive 14-3-3 result. Journal of Neurology, 2016, 263, 1847-1861.	1.8	7
58	Sporadic Creutzfeldt–Jakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3γ assay. Neuroscience, 2016, 322, 398-407.	1.1	25
59	Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic. Molecular Neurobiology, 2016, 53, 2189-2199.	1.9	80
60	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels inÂPatients with Alzheimer's Disease?. Journal of Alzheimer's Disease, 2015, 47, 1069-1078.	1.2	28
61	Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers. Frontiers in Neurology, 2015, 6, 153.	1.1	38
62	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	1.1	36
63	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	1.5	30
64	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
65	Oxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1428-1441.	1.8	137
66	Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. Journal of the Neurological Sciences, 2015, 358, 308-316.	0.3	25
67	Melatonin antiproliferative effects require active mitochondrial function in embryonal carcinoma cells. Oncotarget, 2015, 6, 17081-17096.	0.8	28
68	Progranulin Peripheral Levels as a Screening Tool for the Identification of Subjects with Progranulin Mutations in a Portuguese Cohort. Neurodegenerative Diseases, 2014, 13, 214-223.	0.8	28
69	Vascular, Oxidative, and Synaptosomal Abnormalities During Aging and the Progression of Type 2 Diabetes. Current Neurovascular Research, 2014, 11, 330-339.	0.4	9
70	Rapeseed oil-rich diet alters hepatic mitochondrial membrane lipid composition and disrupts bioenergetics. Archives of Toxicology, 2013, 87, 2151-2163.	1.9	22
71	Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance. Neurobiology of Disease, 2013, 49, 1-12.	2.1	76
72	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344

#	Article	IF	CITATIONS
73	Prodromal Metabolic Phenotype in MCI Cybrids: Implications for Alzheimer's Disease. Current Alzheimer Research, 2013, 10, 180-190.	0.7	30
74	Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation. Current Alzheimer Research, 2012, 9, 881-889.	0.7	48
75	Metabolic Alterations Induced by Sucrose Intake and Alzheimer's Disease Promote Similar Brain Mitochondrial Abnormalities. Diabetes, 2012, 61, 1234-1242.	0.3	129
76	Oxidative stress adaptation in aggressive prostate cancer may be counteracted by the reduction of glutathione reductase. FEBS Open Bio, 2012, 2, 119-128.	1.0	43
77	Differentiation-Dependent Doxorubicin Toxicity on H9c2 Cardiomyoblasts. Cardiovascular Toxicology, 2012, 12, 326-340.	1.1	39
78	Sub-chronic administration of doxorubicin to Wistar rats results in oxidative stress and unaltered apoptotic signaling in the lung. Chemico-Biological Interactions, 2010, 188, 478-486.	1.7	11
79	Oxidative Damage and Progression to Alzheimer's Disease in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 1165-1177.	1.2	78
80	Chronic Hypoxia Potentiates Age-Related Oxidative Imbalance in Brain Vessels and Synaptosomes. Current Neurovascular Research, 2010, 7, 288-300.	0.4	14
81	Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. Journal of Neurology, 2009, 256, 1540-1550.	1.8	48
82	Sporadic Creutzfeldt-Jakob disease causing a 2-years slowly progressive isolated dementia. Behavioural Neurology, 2009, 21, 175-9.	1.1	1
83	Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scandinavian Journal of Gastroenterology, 2008, 43, 95-102.	0.6	79
84	Variant Creutzfeldt Jacob disease: the second case in Portugal and in the same geographical region. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 180-182.	0.9	4
85	Peripheral Oxidative Damage in Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 15, 117-128.	1.2	133
86	Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. European Journal of Clinical Pharmacology, 2006, 62, 737-742.	0.8	11
87	Exome Sequencing of a Portuguese Cohort of Frontotemporal Dementia Patients: Looking Into the ALS-FTD Continuum. Frontiers in Neurology, 0, 13, .	1.1	2